Recursion Pharmaceuticals, Inc. - Class A (RXRX) earnings
RXRX earnings moved a median of -1.98% by the close. Quarterly and annual RXRX reports and results, each read against the price at its own news timestamp. Back to the RXRX overview →
30 measured RXRX earnings events.
Where these RXRX earnings landedvs 29 measured RXRX earnings reactions
| Middle 50% of RXRX earnings reactions | -4.97% to +1.22% |
|---|---|
| Median reaction (to close) | -1.98% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 RXRX earnings events with a measured close landed between -4.97% and +1.22%; 34% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q RECURSION PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | +0.16% | +2.92% | |
| Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th | Press release | +0.49% | -1.98% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -0.16% | +7.52% | |
| Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 | Press release | -1.63% | -2.08% | |
| Form 10-K RECURSION PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | -1.53% | -3.83% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | -0.20% | -1.98% | |
| Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -0.20% | -1.98% | |
| Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th | Press release | -0.75% | -4.68% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -1.34% | -7.06% | |
| Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -1.34% | -7.06% | |
| Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | Press release | -1.04% | — | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | +0.91% | -13.54% | |
| Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.91% | -13.54% | |
| Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th | Press release | +2.25% | +1.21% | |
| Form 10-K RECURSION PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | +6.57% | +12.09% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | -1.01% | -0.29% | |
| Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results | Press release | -1.01% | -0.29% | |
| Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th | Press release | +1.34% | +0.91% | |
| CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | Press release | -0.30% | +1.22% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -0.15% | +2.15% | |
| Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | Press release | -0.15% | +2.15% | |
| Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT | Press release | -0.15% | +2.15% | |
| Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th | Press release | -3.62% | -2.89% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -1.88% | -4.97% | |
| Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results | Press release | -1.88% | -4.97% | |
| Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 | Press release | -0.67% | +3.78% | |
| Form 10-K RECURSION PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | -1.93% | -0.37% | |
| Recursion to Host Public L(earnings) Call on February 27 | Press release | -2.06% | -3.75% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | -4.86% | -10.90% | |
| Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results | Press release | -4.86% | -10.90% |
Keep exploring
More RXRX: analyst actions → · SEC filings → · RXRX overview →